{"version":"1.0","type":"rich","provider_name":"Acast","provider_url":"https://acast.com","height":250,"width":700,"html":"<iframe src=\"https://embed.acast.com/$/65255991eacd800012efb5c5/69de5821ae33864715fd987a?\" frameBorder=\"0\" width=\"700\" height=\"250\"></iframe>","title":"Enveda: Finding Hidden Medicines in Nature","thumbnail_width":200,"thumbnail_height":200,"thumbnail_url":"https://open-images.acast.com/shows/65255991eacd800012efb5c5/1776269221965-68094545-8588-49e3-bde7-63673ef19043.jpeg?height=200","description":"<p>The biotech company Enveda has developed a new approach to explore and ‘decode’ nature’s chemistry. Its goal is to discover molecules that could underpin a new generation of blockbuster drugs. In this podcast, the firm’s founder and chief executive, Viswa Colluru, explains how Enveda could become a trillion-dollar business, and Scottish Mortgage Investment Trust manager Tom Slater considers the risks and opportunities the company faces.</p><p><strong>&nbsp;</strong></p><p><strong>Background:</strong></p><p>Scottish Mortgage first invested in Enveda in November 2024. The US-headquartered company uses a proprietary artificial intelligence (AI) large language model to discover and develop new medicines from natural sources. At the time of writing, it has a pipeline of 12 drug candidates in various stages of development that could form the basis of new therapies to treat dermatitis, obesity, inflammation and chronic pain. Enveda’s founder, Viswa Colluru, has reimagined the drug discovery process from first principles based on his insight that natural molecular compounds should have a better safety profile than engineered ones.“Healthcare is the biggest industry in the world, and if you can increase the odds of success in drug discovery, there are so many unmet needs that its opportunity is effectively unbounded,” says Scottish Mortgage manager, Tom Slater.</p><p>&nbsp;</p><p><strong>Timecodes:</strong></p><p>00:03&nbsp;&nbsp;&nbsp;&nbsp;Coming up…</p><p>00:50&nbsp;&nbsp;&nbsp;&nbsp;Introduction</p><p>02:49&nbsp;&nbsp;&nbsp;&nbsp;Viswa Colluru interview begins</p><p>03:08&nbsp;&nbsp;&nbsp;&nbsp;“Things that work in the lab [often] don’t work in people”</p><p>04:35&nbsp;&nbsp;&nbsp;&nbsp;A mission grounded in a family death</p><p>08:50&nbsp;&nbsp;&nbsp;&nbsp;Invested life savings</p><p>11:24&nbsp;&nbsp;&nbsp;&nbsp;Picking up from where evolution left off</p><p>15:16&nbsp;&nbsp;&nbsp;&nbsp;Using AI to make sense of nature</p><p>21:32&nbsp;&nbsp;&nbsp;&nbsp;A chemistry-first approach</p><p>25:16&nbsp;&nbsp;&nbsp;&nbsp;Historic points of failure</p><p>27:32&nbsp;&nbsp;&nbsp;&nbsp;Reimagining drug discovery from first principles</p><p>29:19&nbsp;&nbsp;&nbsp;&nbsp;Splitting work between US and India</p><p>32:19&nbsp;&nbsp;&nbsp;&nbsp;A growing drug candidate pipeline</p><p>35:07&nbsp;&nbsp;&nbsp;&nbsp;Partnering with Microsoft and Sanofi</p><p>38:19&nbsp;&nbsp;&nbsp;&nbsp;The relationship with Recursion Pharmaceuticals</p><p>41:02&nbsp;&nbsp;&nbsp;&nbsp;“Incredible people looking in unexpected places”</p><p>43:00&nbsp;&nbsp;&nbsp;&nbsp;A globally loved pharma company</p><p>43:38&nbsp;&nbsp;&nbsp;&nbsp;Tom Slater on the investment case</p><p>52:42&nbsp;&nbsp;&nbsp;&nbsp;Podcast lookahead</p><p><br></p><p>Please see our <a href=\"https://media.bailliegifford.com/mws/yl4fk0th/20260422085553_enveda-glossary-of-terms.pdf\" rel=\"noopener noreferrer\" target=\"_blank\">glossary of terms. </a></p><p><br></p><p><strong>Check the podcast description to ensure this content is suitable for you. Your capital is at risk.&nbsp;</strong></p><p><br></p><p><strong>Presenter: Claire Shaw</strong></p><p><strong>Executive Producer: Leo Kelion</strong></p><p><strong>Line producer: Jessica Rooney</strong></p><p><strong>Broadcast Technician: Samual O’Hare </strong></p><p><strong>Editors: Kerry Ingram</strong></p>","author_name":"Scottish Mortgage"}